{"id":"orafang-tab","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Orafang directly inhibits Factor Xa, a key serine protease in the intrinsic and common pathways of blood coagulation. By blocking Factor Xa activity, the drug reduces thrombin generation and subsequent fibrin clot formation, thereby preventing thrombotic events. This mechanism is characteristic of direct Factor Xa inhibitors used in anticoagulation therapy.","oneSentence":"Orafang is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:24:42.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prevention (specific indication under Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT07181148","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of MSP01-T for Bowel Cleansing Before a Colonoscopy","status":"NOT_YET_RECRUITING","sponsor":"Mather's Pharm. Co., Ltd.","startDate":"2025-10","conditions":"Colonoscopy, Bowel Preparation","enrollment":214},{"nctId":"NCT06062030","phase":"PHASE3","title":"Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy;","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-03-08","conditions":"Colonoscopy","enrollment":215},{"nctId":"NCT05670470","phase":"PHASE3","title":"A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 Trial","status":"COMPLETED","sponsor":"Taejoon Pharmaceutical Co., Ltd.","startDate":"2022-09-21","conditions":"Bowel Preparation","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Orafang Tab","genericName":"Orafang Tab","companyName":"Taejoon Pharmaceutical Co., Ltd.","companyId":"taejoon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Orafang is an oral anticoagulant that inhibits Factor Xa in the coagulation cascade to prevent thrombus formation. Used for Thromboembolism prevention (specific indication under Phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}